Why the Bionomics (ASX:BNO) share price surged 8% higher today

The Bionomics share price is marching higher after the company announced that it will exclusively licence its BNC101 drug to Carina.

| More on:
Young doctor raising arms in air with hands in fists celebrating a new development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Bionomics Ltd (ASX: BNO) share price has run higher today after the company announced it has entered an agreement to licence its oncology drug candidate, BNC101, to Carina Biotech. At the market's close, the Bionomics share price had surged 8.33% to 13 cents.

What's pushing the Bionomics share price?

The Bionomics share price has marched higher today after the company advised that it will exclusively licence BNC101 to Carina. The agreement will see the development of Chimeric Antigen Receptor T-cell (CAR-T) therapy using Bionomics' flagship drug. CAR-T is known to harness the body's immune system to fight against cancer.

According to the company, BNC101 is a high-quality, humanised monoclonal antibody to LGR5, which creates copies in cancer stem cells. These occur within solid tumours including colorectal, breast, pancreatic, ovarian, lung, liver and gastric cancers. Bionomics reports that the drug has the potential to guide CAR-T therapeutic development.

Under the agreement, Carina will fund all research and development activities. Bionomics is eligible to receive up to $118 million in clinical and development milestones plus royalties. This is based on the terms that Carina can develop and market the new therapy.

Should Carina decide to sub-licence the CAR-T treatment, Bionomics will be eligible to share in the sub-licencing revenues in early clinical development. If later stages of development are reached, Bionomics has advised it will receive "a substantial double-digit portion of revenues".

Management commentary

Bionomics Executive Chair, Dr Errol De Souza, spoke about the new partnership. He said:

We are very excited to have entered into this agreement with Carina Biotech given the opportunity CAR-T therapy offers. This innovative approach has the potential to create a new cancer treatment.

Bionomics retains BNC101 for other types of therapies and is continuing to search for such opportunities. This is in keeping with our corporate strategy to leverage value for our clinical oncology assets by working with other companies bringing proprietary technology to the table and providing full funding to progress development of our assets.

About the Bionomics share price

The Bionomics share price has fallen from grace over the past few years. In 2018, shares in the biopharma company reached as high as 59 cents, with today's closing price representing nearly an 80% decline from these levels.

The company has a market capitalisation of $95.6 million. Only time will tell whether the Bionomics share price can regain its former glory.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A young woman sits on her bed holding a cup of coffee inside her recreational vehicle hired through the Camplify website
Cheap Shares

2 cheap ASX shares to add to your portfolio before they get expensive

I reckon this duo could see their stock prices rocket after they brush off temporary setbacks.

Read more »

Business woman watching stocks and trends while thinking
Share Market News

5 things to watch on the ASX 200 on Thursday

Will investors be leaping for joy on 29 February?

Read more »

A young man goes over his finances and investment portfolio at home.
Growth Shares

1 ASX growth stock down 30% to buy right now

The market has reacted badly to this ASX 200 company's half-year result. This could be your chance to get in.

Read more »

A female miner wearing a high vis vest and hard hard smiles and holds a clipboard while inspecting a mine site with a colleague.
Share Market News

Here's the Rio Tinto dividend forecast through to 2026

Here's what analysts are forecasting for the miner's dividend.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Dividend Investing

How I'd invest $250 a month in ASX dividend shares to target a $24,000 annual second income

Passive income is within the reach of ordinary Aussies, just like you. Yes, I said you!

Read more »

A man looking at his laptop and thinking.
Share Gainers

Should I buy Nvidia stock as an Australian investor?

Many Aussies are thinking of jumping on the bandwagon, but they need to think about these issues first.

Read more »

A woman sits in a cafe wearing a polka dotted shirt and holding a latte in one hand while reading something on a laptop that is sitting on the table in front of her
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough day for ASX 200 investors this Wednesday.

Read more »

Smiling man working on his laptop.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »